| 25-6287 |
Marcus Brent Fields v. Pfizer Inc., et al. |
Second Circuit |
2025-12-04 |
Denied |
IFP |
corporate-ethics drug-development federal-violations pharmaceutical-liability regulatory-compliance securities-law |
a) Pfizer Defendands Knew there Courd ~ TO yotene Lot RA boy ,
Could ~ Cause more Sever and or Heard damage body orguns damage
eS pecially Ceeapmet Am… |
| 24-977 |
Merck Sharp & Dohme Corporation v. Doris Albrecht, et al. |
Third Circuit |
2025-03-12 |
Denied |
Amici (4) |
administrative-law drug-preemption fda-regulation pharmaceutical-liability state-law-liability warning-label |
If a pharmaceutical manufacturer fully informs the FDA of all material information bearing on a drug's potential risk and seeks approval to warn of th… |
| 24A720 |
Merck Sharp & Dohme Corporation v. Doris Albrecht, et al. |
Third Circuit |
2025-01-22 |
Presumed Complete |
|
drug-labeling failure-to-warn federal-regulations pharmaceutical-liability preemption product-liability |
Question not identified. |
| 21-1238 |
Ina Ann Rodman v. Otsuka America Pharmaceutical, Inc. |
Ninth Circuit |
2022-03-11 |
Denied |
Response Waived |
21-cfr-314-80 design-defect drug-labeling expert-testimony failure-to-warn misbranding pharmaceutical-liability post-marketing-surveillance summary-judgment wyeth-v-levine |
1. Whether Ms. Rodman presented admissible evidence in the form of Otsuka's failure to follow the admonition of 21 C.F.R. § 314.80 to conduct post-mar… |
| 18-1502 |
Brian Mark Burmaster v. Eli Lilly and Company |
Sixth Circuit |
2019-06-03 |
Denied |
|
6th-amendment civil-rights constitutional-rights drug-marketing due-process free-speech government-action government-intervention government-overreach government-regulation medical-ethics pharmaceutical pharmaceutical-liability pharmaceutical-litigation sixth-amendment |
If a company's manufactured and marketed product, such as Eli Lilly's Zyprexa is cited by the US Government Quack (called a medical doctor?) as the mi… |